论文部分内容阅读
目前全球约1.75亿人为慢性丙型肝炎患者,慢性丙型肝炎是一个全球性的健康问题[1]。目前慢性丙型肝炎的标准治疗方案为PEG-IFN-α加利巴韦林。两药治疗过程中会出现一定的不良的反应,部分患者无法坚持完成足疗程治疗,足量足疗程治疗对取得持续病毒学应答至关重要,故需重视药物的不良反应[2]。早期发现不良反应并积极处理能够帮助患者坚持完成疗程。现就本院20例使用上述方案的治疗慢性丙型肝炎患者的疗效及不良反应报道如下。
At present, about 175 million people in the world are patients with chronic hepatitis C, and chronic hepatitis C is a global health problem [1]. The current standard treatment for chronic hepatitis C is PEG-IFN-α plus ribavirin. Two drugs will appear in the course of treatment of some adverse reactions, some patients can not insist on completing the full course of treatment, enough course of treatment is essential to achieve sustained virological response, it should pay attention to the adverse drug reactions [2]. Early detection of adverse reactions and active treatment can help patients adhere to the completion of treatment. Now on the hospital in 20 cases of the use of the above treatment of chronic hepatitis C patients with adverse reactions and adverse reactions are reported below.